Navigation Links
Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin

rom this study have enabled us to make the decision to progress to phase III development of pertuzumab in breast cancer," commented Jean-Jacques Garaud, Head of Development, Roche. "We will be investigating the effectiveness of pertuzumab in the metastatic setting and also exploring its use in early breast cancer prior to surgical removal of the tumour."

About the study This is a non-randomised Phase II study, conducted in two-stages: patients were assessed to ensure that the therapy is tolerable and that there is a reasonable minimum level of activity. Eligible patients must have measurable, centrally-tested progressive HER2 positive breast cancer and had received up to 3 courses of prior chemotherapy plus Herceptin and the disease must have progressed during Herceptin therapy . During the study patients received Herceptin i.v weekly or every 3 weeks at 2 mg/kg or 6 mg/kg respectively and 420mg of pertuzumab i.v. every 3 weeks after a loading dose of 840mg. The criteria to proceed to the 2nd stage were: > 2 partial responses (PR), or 1 PR and 12 patients with stable disease (SD), or 13 patients with SD.

Out of 33 patients who had passed the first assessment point at the time of the data cut off, 1 had a complete response and 5 had partial responses giving a response rate of 18.2%. A further 7 patients have had stabilization of disease lasting 6 months or more (21.2%). Recruitment into stage 2 of the trial is ongoing.

As well as evaluating pertuzumab in breast cancer Roche and Genentech are evaluating pertuzumab in ovarian cancer in combination with other therapies. Results from a phase II platinum resistant ovarian cancer study will be presented at ASCO on Sunday 3rd June 1-4pm.

About breast cancer Breast cancer is the most common cancer among women worldwide (2). Each year more than one million new cases of breast cancer are diagnosed worldwide, and nearly 400,000 people will die of the disease annually. In HER2-positive breast cancer,
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ADVENTRX Presents Results at Keystone Symposia HIV ... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ) ... the Company,s broad-spectrum antiviral product candidate at ... Alberta on March,30, 2008. The preclinical results ...
... Arterial renarrowing less likely, with no increase in mortality on ... ... stents have,become widely used for the treatment of stable coronary artery ... infarction (MI), citing conflicting data about the safety and,effectiveness of drug-eluting ...
Cached Medicine Technology:ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 2ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 3ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests 4Large Study Gives Nod to Drug-Eluting Stents in Heart Attack 2Large Study Gives Nod to Drug-Eluting Stents in Heart Attack 3
(Date:7/13/2014)... Recently, iFitDress.com, one of the most famous ... collection of brown evening dresses for worldwide ... at discounted prices, up to 50% off. , ... they are carefully made according to most fashionable styles. ... also offers pretty accessories: wedding shoes, dancing shoes, sandals, ...
(Date:7/13/2014)... (PRWEB) July 14, 2014 MillionaireCasket.com is a ... manager, its excellent wood caskets are selling well in the ... of cherry caskets and launched a special offer ... the low prices, all the company’s cherry caskets are made ... is a must for people to show respect to the ...
(Date:7/13/2014)... and variations in the quality of care are the ... still varies widely between regions within Europe, according to ... to date, published in The Lancet Oncology . ... most cancers of the blood has increased over the ... new targeted drugs in the early 2000s such as ...
(Date:7/13/2014)... Carolinas Healthcare System celebrated today the ... HealthCare System - Anson located in Anson County. The ... Hospital in Wadesboro. , Located on U.S. Highway 74, ... previous facility. Situated on a 10-acre site, the new ... room drop-off, helipad, healing garden, and 15 beds. With ...
(Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
Breaking Medicine News(10 mins):Health News:2014 Brown Evening Dresses Added To iFitDress.com 2Health News:Brand New Cherry Caskets Unveiled By China Casket Supplier MillionaireCasket.com 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 2Health News:The Lancet Oncology: Differences in treatment likely to be behind differing survival rates for blood cancers between regions within Europe 3Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3
... on Sunday became the first US city to banish trans ... uphill struggle in forcing some eateries to display calorie ... New York's 20,000 restaurants, the transition towards healthier cooking oils ... degree of reluctance. ,At the heart of the ...
... for superstition and marketing to come together: starry-eyed couples are ... concerts as well as the proclamation of the world's seven ... has a magic sacred side and the reputation of bringing ... an extra dose of good fortune. ,"Number 7 ...
... but it seems as though capitalism is bad for men's ... in mortality rates after the collapse of the Soviet Union. ... the Iron Curtain dropped by six years between 1991 and ... ,The degree to which men were affected depended upon ...
... for INVEGA(TM) (paliperidone prolonged release tablets), an ... schizophrenia. This once-daily medication is specifically ... ingredient in INVEGA - through the innovative ... INVEGA demonstrated significant efficacy as compared to ...
... germ cell tumour patients treated with platinum-based chemotherapy ... function and reproductive ability. ,The ... also found that despite having reproductive and sexual ... counterparts to be involved in meaningful, positive relationships. ...
... of Calgary in Alberta have shown that female mice tend ... male's urine, a discovery that outlines how chemical messages ... Samuel Weiss and his colleagues at the university looked at ... animals use to recognize and choose their mates, on the ...
Cached Medicine News:Health News:New York Bans Trans Fats in Restaurants 2Health News:New York Bans Trans Fats in Restaurants 3Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3Health News:Capitalism is Bad for Men's Health: Study 2Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 2Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 3Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 4Health News:INVEGA Receives Marketing Authorization In EU For Treatment Of Schizophrenia 5Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 2Health News:Survivors of Rare Ovarian Cancer may Retain Menstrual Function and Reproductive Ability 3Health News:Male Pheromones Build Brain Cells in Female Mice 2
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Stainless steel disposable retinal MVR blade, 10 pcs / box....
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Refresh Contacts provides moisturizing relief from dryness and irritation associated with lens wear....
Medicine Products: